2.4 Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves the Unfavorable M1/M2- Like Phenotypes of Peripheral Blood Monocytes in Japanese Type 2 Diabetic Patients (377-OR)

2013 ◽  
Vol 11 (3) ◽  
pp. 84-84
Author(s):  
Noriko Satoh-Asahara ◽  
Shinji Odori ◽  
Yousuke Sasaki ◽  
Hajime Yamakage ◽  
Kazuya Muranaka ◽  
...  
Keyword(s):  
Peripheral Blood ◽  
Dipeptidyl Peptidase ◽  
Diabetic Patients ◽  
Blood Monocytes ◽  
Type 2 Diabetic Patients ◽  
Peripheral Blood Monocytes ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Type 2 Diabetic

A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients

Metabolism ◽  
2013 ◽  
Vol 62 (3) ◽  
pp. 347-351 ◽  
Author(s):  
Noriko Satoh-Asahara ◽  
Yousuke Sasaki ◽  
Hiromichi Wada ◽  
Mayu Tochiya ◽  
Azusa Iguchi ◽  
...  
Keyword(s):  
Dipeptidyl Peptidase ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Dipeptidyl Peptidase 4 Inhibitor ◽  
Anti Inflammatory ◽  
Type 2 Diabetic

scholarly journals The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

2011 ◽  
Vol 58 (11) ◽  
pp. 979-987 ◽  
Author(s):  
Midori Ito ◽  
Masanori Abe ◽  
Kazuyoshi Okada ◽  
Hirokazu Sasaki ◽  
Noriaki Maruyama ◽  
...  
Keyword(s):  
Glycemic Control ◽  
Dipeptidyl Peptidase ◽  
Diabetic Patients ◽  
Type 2 Diabetic Patients ◽  
Dipeptidyl Peptidase 4 ◽  
Type 2 Diabetic
Sign in / Sign up

Export Citation Format

Share Document